| Literature DB >> 34007963 |
Bruce M Robinson1, Murilo Guedes2, Mohammed Alghonaim3,4, Aleix Cases5, Indranil Dasgupta6, Liangying Gan7, Stefan H Jacobson8, Talerngsak Kanjanabuch9, Yong-Lim Kim10, Werner Kleophas11,12, Laura Labriola13, Rachel L Perlman14, Gianpaolo Reboldi15, Vesh Srivatana16,17, Rita S Suri18, Kazuhiko Tsuruya19,20, Pablo Urena Torres21, Ronald L Pisoni1, Roberto Pecoits-Filho1,2.
Abstract
As the worst global pandemic of the past century, COVID-19 has had a disproportionate effect on maintenance dialysis patients and their health care providers. At a virtual roundtable on 12 June 2020, DOPPS investigators from fifteen countries in Asia, Europe, and the Americas described and compared the effects of COVID-19 on dialysis care, with recent updates added. Most striking is the huge difference in risk to dialysis patients and staff across the world. Per-population cases and deaths among dialysis patients vary over 100-fold across participating countries, mirroring burden in the general population. International data indicate case fatality ratio remains at 10-30% among dialysis patients, confirming the gravity of infection, and that cases are much more common among in-center than home dialysis patients. This latter finding merits urgent study because in-center patients often have greater community exposure, and in-center transmission may be uncommon under optimal protocols. Greater telemedicine use is a welcome change here to stay, and our community needs to improve emergency planning and protect dialysis staff from the next pandemic. Finally, the pandemic's challenges have prompted widespread partnering and innovation in kidney care and research that must be sustained after this global health crisis.Entities:
Keywords: COVID-19; DOPPS; International; dialysis; risk
Year: 2021 PMID: 34007963 PMCID: PMC8120787 DOI: 10.1016/j.xkme.2021.03.006
Source DB: PubMed Journal: Kidney Med ISSN: 2590-0595
Figure 1Coronavirus disease 2019 (COVID-19) cases and deaths in general population, by participating country. Peak cases per day, per 100,000 population for (A) January to August 2020 and (B) September 2020 to January 2021. (C) Cumulative cases, per 100,000 population (as of January 31, 2021). (D) Cumulative deaths, per 100,000 population (as of January 31, 2021). Abbreviations: BE, Belgium (A: April 15, 2020; B: October 29, 2020); BR, Brazil (A: July 29, 2020; B: January 7, 2021); CA, Canada (A: April 5, 2020; B: January 3, 2021); CN, China (A: February 13, 2020; B: January 21, 2021); DE, Germany (A: March 27, 2020; B: December 30, 2020); ES, Spain (A: August 31, 2020; B: January 25, 2021); FR, France (A: April 12, 2020; B: November 2, 2020); IT, Italy (A: March 21, 2020; B: November 13, 2020); JP, Japan (A: July 30, 2020; B: January 8, 2021); KR, South Korea (A: March 3, 2020; B: December 24, 2020); SA, Saudi Arabia (A: June 17, 2020; B: September 1, 2020); SE, Sweden (A: June 14, 2020; B: December 29, 2020); TH, Thailand (A: March 22, 2020; B: January 29, 2021); UK, United Kingdom (A: April 2, 2020; B: January 8, 2021); US, United States (A: July 16, 2020; B: January 2, 2021). Source: Our World in Data.
Figure 2Proportion of coronavirus disease 2019 (COVID-19) cases among kidney replacement therapy (KRT) patients, by modality. Most recent data as of: (A) August 31, 2020, and (B) January 31, 2021. Data are from Table 1. Red bar indicates in-center hemodialysis (HD) except (∗) all dialysis for France (FR) and (∗∗) all KRT for United States (US). Abbreviations: BE, Belgium; BR, Brazil; CA, Canada; DE, Germany; ES, Spain; IT, Italy; JP, Japan; KR, South Korea; SA, Saudi Arabia; TH, Thailand; UK, United Kingdom.
Confirmed COVID-19 Cases and Case-Fatality Ratios Among Patients Receiving Kidney Replacement Therapy, by Participating Country
| No. of KRT Patients (% in-center HD, home dialysis, transplant) | Date for COVID-19 Data | Cases by KRT Modality | Case-Fatality Ratio by KRT Modality | Source of COVID-19 Data; Comments | |||||
|---|---|---|---|---|---|---|---|---|---|
| In-center HD | Home Dialysis | Transplant | In-center HD | Home Dialysis | Transplant | ||||
| Belgium | 14,797 (51%, 5%, 44%) | 5/31/20 | 8.6% | 4.1% | — | 18.6% | 10% | – | Groupement de Néphrologues Francophones de Belgique Registry |
| United Kingdom | 66,612 (37%, 7%, 56%) | 6/3/20 | 9.8% | 2.5% | 1.2% | 25.3% | 41.2% | 27% | UK Renal Registry |
| 12/29/20 | 17.3% | 6% | 2.7% | 19.6% | 22.5% | 16.8% | |||
| Spain | 61,764 (40%, 5%, 55%) | 7/4/20 | 4.6% | 1.8% | 1.6% | 27% | 21% | 24% | Spanish Society of Nephrology Registry |
| 1/2/21 | 8% | PD 3.7%/HHD 4.3% | 4.1% | 26.7% | PD 23.4%/HHD 12.5% | 19.6% | |||
| Italy | 60,441 | 4/23/20 | 3.6% | 1.4% | 0.9% | 34% | 46% | 25% | Italian Society of Nephrology COVID Survey |
| France | 87,275 (51%, 4%, 45%) | 7/8/20 | 3.9% (all dialysis) | — | 1.3% | 14.2% (all dialysis) | — | 19% | Renal Epidemiology and Information Network Registry |
| 12/2/20 | 9.0% (all dialysis) | — | 3.0% | 15.0% | — | 14.0% | |||
| Germany | — | 5/24/20 | 2% | — | — | 20% | — | — | German Covid-19 Dialysis Registry; preliminary data from 14,000 patients |
| United States | 733,010 (63%, 8%, 29%) | 6/11/20 | 3.8% (all KRT) | — | — | 24.9% | — | — | Cases from Medicare preliminary COVID-19 data snapshot report, shown for Medicare-only patients |
| 11/21/20 | 9.8% (all KRT) | — | |||||||
| Canada | 37,647 (44%, 14%, 42%) | 7/9/20 | 3.3% | — | — | 22.5% | — | — | COVID-19 data for Ontario and Quebec only; cases were <0.1% in other provinces. Sources: Ontario: Ontario Renal Reporting System and Ontario Renal Network. Quebec: author communication with medical directors |
| Brazil | 133,500 (92%, 8%, —) | 7/30/20 | 3.4% | 28% | National survey by Brazilian Society of Nephrology and Brazilian Association of Dialysis and Transplant Centers | ||||
| Saudi Arabia | 27,599 (64%, 5%, 31%) | 7/21/20 | 1.2% | 0.3% | 2.7% | 7.0% | 0% | 4.8% | Author communication with Saudi Center for Organ Transplantation (Alghonaim, February 2021) |
| 12/31/20 | 7.4% | 1.5% | 4.1% | 13.4% | 10% | 7.3% | |||
| Japan | 372,508 (95%, 3%, 2%) | 8/7/20 | <0.1% (158 cases) | <0.1% (2 cases) | — | 14% (22 deaths) | 0% | — | Japanese Association of Dialysis Physicians |
| 12/25/20 | 0.1% (513 cases) | 0.1% (9 cases) | — | 13.3% (68 deaths) | 33.3% (3 deaths) | — | |||
| Korea | 108,873 (75%, 6%, 19%) | 7/5/20 | <0.1% (23 cases) | 0% (no cases) | <0.1% (6 cases) | 13% (3 deaths) | No cases | 1 death | Korean Society of Nephrology COVID-19 Task Force Team ( |
| 1/8/21 | 0.13% (107 cases) | 0% (no cases) | <0.1% (6 cases) | 8 (9 deaths) | No cases | 1 death | |||
| Thailand | 99,760 (68%, 27%, 5%) | 7/12/20 | 0% (no cases) | <0.1% (1 case) | <0.1% (3 cases) | No cases | 1 death | 0% | Author communication with Nephrology Society of Thailand(Adisorn Lampaopong, MD) and Thai Transplantation Society (Natavudh Townamchai, MD), January 2021 |
| 1/31/21 | 0% (no cases) | <0.1% (1 case) | <0.1% (4 cases) | No cases | 1 death | 1 death | |||
Note: For each country, most recent data from January 2020 to August 2020 are provided in first row; if available, most recent data from September 2020 to January 2021 are provided in second row. Data not available for cells with “—”. Countries not shown: Sweden (national data collection underway by the Swedish Renal Registry) and China (national data not available; see text for regional publications).
Abbreviations: COVID-19, coronavirus 2019; HD, hemodialysis; HHD, home hemodialysis; KRT, kidney replacement therapy; PD, peritoneal dialysis.
Number (modality) of KRT patients from US Renal Data System 2018 Annual Data Report, except Italy and Korea.
If <1%, number of cases is provided; cases by KRT modality are also shown in Fig 2.
Number of patients at sites responding to the COVID-19 Survey, comprising 90% of KRT patients in Italy.
National data not available for case-fatality ratio in United States; case-fatality ratio of 24.9% was among 438 patients with COVID-19 infection at a mid-size national dialysis provider (as of June 1, 2020).
Figure 3Cumulative coronavirus disease 2019 (COVID-19) (A) cases and (B) deaths (as percent of all dialysis patients) by cumulative deaths per 100,000 in general population. Dialysis data are shown for in-center hemodialysis (HD) patients except for France (FR; all dialysis patients) and United States (US; all kidney replacement therapy patients). Population data are as of date of dialysis data. Abbreviations: BE, Belgium (1: May 2020); BR, Brazil (1: July 2020); CA, Canada (1: July 2020); DE, Germany (1: July 2020); ES, Spain (1: July 2020; 2: January 2021); FR (1: July 2020; 2: December 2020); IT: Italy (1: April 2020); JP, Japan (1: August 2020; 2: December 2020); KR: South Korea (1: July 2020; 2: January 2021); SA, Saudi Arabia (1: July 2020; 2: December 2020); TH, Thailand (1: June 2020); UK, United Kingdom (1: June 2020; 2: December 2020); US (1: July 2020; 2: November 2020). Source: Table 1 (dialysis data) and Our World in Data (population data).
Figure 4Examples of information sharing, partnering, and innovation during the coronavirus disease 2019 (COVID-19) pandemic that we can learn from to accelerate transformation after the pandemic ends. Abbreviations: CSN, Canadian Society of Nephrology; NICE, National Institute for Health and Care Excellence; RRT, renal replacement therapy.
Panelists’ Impressions About the Impact of COVID-19 on Dialysis Practice Locally
| In your local practice region, how did/do the following differ during the early COVID-19 period compared with before COVID-19? | Which changes will persist during the next year or beyond, compared with before COVID-19? | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of Kidney Transplants | Home Dialysis Use | Use of Telemedicine for Home Dialysis Support | Use of Urgent- or Acute-Start PD | Treatment Time/wk for In-center HD Patients | Availability of Dialysis Access Procedures | Transportation to/From Dialysis Unit | Morale Among In-center HD Patients | Morale Among Dialysis Unit Staff | ||
| Belgium | ↓↓ | – | ↑↑ | NA | – | – | ↓ | ↓↓ | ↓ | Greater use of telemedicine; mask use for all patients/staff over at least the next y; morale remains decreased |
| United Kingdom | ↓↓ | ↑ | ↑↑ | ↑ | ↓ | ↓↓ | ↓ | ↓ | ↓↓ | Greater use of telemedicine, home dialysis, and twice-weekly HD at initiation |
| Spain | ↓↓ | – | ↑↑ | – | ↓ | ↓ | ↓ | ↓↓ | ↓↓ | Some personnel have been diagnosed with posttraumatic syndrome |
| Italy | ↓↓ | ↑ | ↑ | NA | – | – | ↓↓ | ↓ | ↓↓ | Greater use of telemedicine; we are recommending greater use of home therapy |
| Sweden | ↓↓ | – | ↑ | NA | ↓ | ↓ | ↓ | ↓ | ↓ | Greater use of telemedicine; we are aiming to increase use of home therapy |
| France | ↓↓ | ↑ | ↑ | NA | ↓ | – | – | ↓ | ↓ | Morale remains decreased |
| Germany | ↓ | – | – | – | – | ↓ | ↓ | – | – | Home dialysis use will continue to grow |
| United States (Ann Arbor) | ↓ | – | ↑↑ | – | – | ↓ | – | ↓ | ↓ | Greater use of telemedicine |
| United States (N Y) | ↓↓ | ↑ | ↑↑ | ↑↑ | ↓ | ↓↓ | ↓↓ | ↓↓ | ↓↓ | Greater use of telemedicine |
| Brazil | ↓↓ | ↓ | ↑↑ | – | – | ↓↓ | ↓ | ↓↓ | ↓↓ | Greater use of telemedicine |
| Canada | ↓↓ | ↓ | ↑ | – | – | – | ↓ | – | ↓ | Greater use of telemedicine will persist, home dialysis use expected to increase |
| Saudi Arabia | ↓↓ | – | ↑↑ | NA | ↓ | ↓ | – | ↓ | ↓ | Greater use of telemedicine |
| Japan | ↓↓ | – | – | – | – | – | – | ↑ | ↓↓ | Longer-term changes not expected |
| Korea | – | – | – | NA | – | – | – | ↓ | – | Longer-term changes not expected |
| China | ↓ | – | – | ↑ | – | ↓ | ↓ | – | ↓ | Longer-term changes not expected |
| Thailand | ↓↓ | – | ↑↑ | ↑ | – | ↓ | ↓ | ↓ | ↓ | Telemedicine use will remain higher, and we will strive to increase use of urgent-/acute-start PD |
Note: Panelists were asked to state impact on practice during the pandemic’s peak to date, as of August 2020.
Abbreviations: COVID-19, coronavirus disease 2019; HD, hemodialysis; NA, urgent or acute-start peritoneal dialysis is not available; PD, peritoneal dialysis.
Answer options: markedly decreased/worsened (↓↓), somewhat decreased/worsened (↓), unchanged (–), somewhat increased/improved (↑), markedly increased/improved (↑↑) .
Reference 56 provides another example of use of acute PD.
Question: How did treatment time per week change due to changes in prescription, adherence, availability of supplies, etc (↓ = shorter, ↑ = longer)?
Question: Did transportation of patients to/from the dialysis unit become easier (↑) or more challenging (↓)?
Reference 8.